Antitumour activity of an inhibitor of miR-34a in liver cancer with {beta}-catenin-mutations

Conclusions
This work demonstrates the key oncogenic role of miR-34a in liver tumours with β-catenin gene mutations. We suggest that patients diagnosed with HCC with β-catenin mutations could be treated with an inhibitor of miR-34a. The potential value of this strategy lies in the modulation of the tumour suppressor HNF-4α, which targets cyclin D1, and the induction of a proapoptotic programme.

Source: Gut - May 9, 2016 Category: Gastroenterology Authors: Gougelet, A., Sartor, C., Bachelot, L., Godard, C., Marchiol, C., Renault, G., Tores, F., Nitschke, P., Cavard, C., Terris, B., Perret, C., Colnot, S. Tags: Colon cancer, Hepatic cancer Hepatology Source Type: research